HISTONE-LYSINE N-METHYLTRANSFERASE EZH2

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Approval Year

Substance Class	Protein Created by `admin` on `Tue Apr 01 19:52:27 GMT 2025` Edited by `admin` on `Tue Apr 01 19:52:27 GMT 2025`
Protein Sub Type
Sequence Type	COMPLETE
Record UNII	J2234208AE
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ENHANCER OF ZESTE 2 (HUMAN CELL LINE BJA-B GENE EZH2)

Preferred Name

English

HISTONE-LYSINE N-METHYLTRANSFERASE EZH2

Common Name

English

LYSINE N-METHYLTRANSFERASE 6

Common Name

English

ENHANCER OF ZESTE HOMOLOG 2

Common Name

English

ENX-1

Common Name

English

KMT6

Common Name

English

Code System Code Type Description

WIKIPEDIA

EZH2

Created by admin on Tue Apr 01 19:52:27 GMT 2025 , Edited by admin on Tue Apr 01 19:52:27 GMT 2025

PRIMARY

CAS

459578-94-0

Created by admin on Tue Apr 01 19:52:27 GMT 2025 , Edited by admin on Tue Apr 01 19:52:27 GMT 2025

PRIMARY

UNIPROT

Q15910

Created by admin on Tue Apr 01 19:52:27 GMT 2025 , Edited by admin on Tue Apr 01 19:52:27 GMT 2025

PRIMARY

FDA UNII

J2234208AE

Created by admin on Tue Apr 01 19:52:27 GMT 2025 , Edited by admin on Tue Apr 01 19:52:27 GMT 2025

PRIMARY

PHAROS

Q15910

Created by admin on Tue Apr 01 19:52:27 GMT 2025 , Edited by admin on Tue Apr 01 19:52:27 GMT 2025

PRIMARY

CAS

487555-47-5

Created by admin on Tue Apr 01 19:52:27 GMT 2025 , Edited by admin on Tue Apr 01 19:52:27 GMT 2025

ALTERNATIVE

EC (ENZYME CLASS)

EC 2.1.1.43

Created by admin on Tue Apr 01 19:52:27 GMT 2025 , Edited by admin on Tue Apr 01 19:52:27 GMT 2025

PRIMARY

Glycosylation Type

HUMAN

Glycosylation Link Type	Site
O	1_75

Related Record Type Details


					Q40W93WPE1

INHIBITOR -> TARGET

Comments:

biochemical assay

Qualification:

IC50

Amount:


					455J2479FY

INHIBITOR -> TARGET


					S4L4MM20B6

INHIBITOR -> TARGET

Qualification:

Ki

Amount:


					W4OGW9QZ97

INHIBITOR -> TARGET

Comments:

The maximal dose and schedule attained with GSK2816126 has shown insufficient evidence of clinical activity, and does not justify further clinical investigation.

Structural Modifications

Modification Type	Location Site	Location Type	Residue Modified	Extent	Fragment Name	Fragment Approval
AMINO ACID SUBSTITUTION	[1_345]		THREONINE		THREONINE PHOSPHATE	3L4WX7B1EI
AMINO ACID SUBSTITUTION	[1_339] [1_367] [1_487]		THREONINE		THREONINE PHOSPHATE	3L4WX7B1EI
AMINO ACID SUBSTITUTION	[1_76] [1_363] [1_366]		SERINE		DEXFOSFOSERINE	VI4F0K069V
AMINO ACID SUBSTITUTION	[1_21]		SERINE		DEXFOSFOSERINE	VI4F0K069V

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
MOL_WEIGHT:NUMBER AVERAGE(CALCULATED)	CHEMICAL